Financial updates
Pharming Group Report on Preliminary Financial Results for 2016
Pharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.
‘’2016 was a major year for Pharming. During the year we achieved a number of positive milestones that culminated in December in the game-changing re-acquisition of commercialization rights for RUCONEST® in North America"
- Sijmen de Vries - CEO